





Supplementary Figure S1 Determination of C₄₄Mab-3 epitope by ELISA. Fifty-eight synthesized peptides, which cover the CD44v3–10 extracellular domain, were immobilized on immunoplates. The plates were incubated with C₄₄Mab-3, followed by incubation with peroxidase-conjugated anti-mouse immunoglobulins. Optical density was measured at 655 nm. ELISA, enzymelinked immunosorbent assay. NC, negative control (solvent; DMSO in PBS).

A**CHO/CD44v3-10****B****CHO/CD44s****C****CHO-K1**

Supplementary Figure S2 Recognition of CHO/CD44s and CHO/CD44v3-10 by C₄₄Mab-46 using flow cytometry. CHO/CD44v3-10 (A), CHO/CD44s (B), and CHO-K1 (C) were treated with 0.01-10 µg/mL of C₄₄Mab-46, followed by treatment with Alexa Fluor 488-conjugated anti-mouse IgG (Red line). The black line represents the negative control (blocking buffer).


CD44p311-330




Supplementary Figure S3 Measurement of dissociation constants (K_D) between C₄₄Mab-3 and the epitope peptide using SPR.

The binding kinetics and measured values of C₄₄Mab-3 with CD44p311-330 peptide. SPR, surface plasmon resonance.









C₄₄Mab-3



C₄₄Mab-46



Supplementary Figure S4 Immunohistochemical analysis using C₄₄Mab-3 and C₄₄Mab-46 against oral squamous cell carcinoma tissue. After antigen retrieval, the sections were incubated with 5 $\mu\text{g/mL}$ of C₄₄Mab-3 (A) and 1 $\mu\text{g/mL}$ of C₄₄Mab-46 (B), followed by treatment with the Envision+ kit. The color was developed using 3,3'-diaminobenzidine tetrahydrochloride (DAB), and the sections were counterstained with hematoxylin. Scale bar = 100 μm .

A**C₄₄Mab-3****B****C₄₄Mab-46****C****C₄₄Mab-3****D****C₄₄Mab-46****E****C₄₄Mab-3****F****C₄₄Mab-46****G****C₄₄Mab-3****H****C₄₄Mab-46**

Supplementary Figure S5. Immunohistochemical analysis using C₄₄Mab-3 and C₄₄Mab-46 against pancreatic adenocarcinomas and normal pancreatic tissues. After antigen retrieval, serial sections of pancreatic carcinoma tissue arrays (Catalog number: PA241c) were incubated with 1 μ g/mL of C₄₄Mab-3 or C₄₄Mab-46 followed by treatment with the Envision+ kit. The color was developed using 3,3'-diaminobenzidine tetrahydrochloride (DAB), and the sections were counterstained with hematoxylin. Scale bar = 100 μ m. (A–F) pancreatic adenocarcinomas; (G, H) normal pancreas tissues.

(A) C₄₄Mab-3 showed the membranous staining in pancreatic carcinoma cells with relatively larger cytoplasm, but not surrounding ductal structure of PDAC and stromal tissues. (B) C₄₄Mab-46 stained both type of PDAC. (C, D) The diffusely spread tumor cells in stroma were stained by both C₄₄Mab-3 and C₄₄Mab-46. (E, F) In well-differentiated PDAC, both C₄₄Mab-3 and C₄₄Mab-46 never stained the tumor cells. (F) In addition, stromal staining by C₄₄Mab-46 was observed in several tissues. (G) Importantly, normal pancreatic epithelial cells were never stained by C₄₄Mab-3.